Skip to main content
Funded Studies

Magdalene M. Moran, PhD

Chief Scientific Officer at Rheostat Therapeutics

Location: Cambridge, MA United States

Dr. Magdalene Moran is the Chief Scientific Officer, leading research and development at Rheostat Therapeutics. She received her PhD in 2002 from the Laboratory of Dr. David Clapham in the Program in Neuroscience at Harvard University, where she studied transcriptional regulation and cloned several novel ion channels (CatSpers 3 and 4, the voltage-gated channel Hv1, and TRPV3).

For the past 15 years, Dr. Moran has led drug discovery efforts on ion channels. This work elucidated the role of TRPA1 in cold hypersensitivity and helped define the function of TRPC4/5 - containing ion channels in anxiety and depression. The team she led identified six development candidates in the last six years and three molecules that entered human clinical trials for pain or CNS disorders.

Dr. Moran is the inventor on more than 50 published patent applications and issued patents directed at ion channel modulators.

Associated Grants

  • Assessing TRPML1 Agonists in GBA Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.